Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMounjaro typically begins working within the first week, though the effects build gradually over months. Most people notice some reduction in appetite during the first pen, but meaningful weight change usually becomes visible by weeks four to eight. These are prescription-only medicines; a prescriber assesses whether they're clinically right for you before treatment starts. The timeline below follows what actually happens, dose by dose, so you know what to expect rather than wondering whether it's working.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The first pen contains four weekly doses, all at 2.5 mg. That dose exists for one reason: tolerance. Your digestive system needs time to adapt to tirzepatide's effect on gastric emptying, and starting low reduces the nausea and stomach discomfort that higher doses can cause from day one. Some people feel a noticeable dip in appetite within the first few days. Others notice nothing dramatic for the first fortnight. Both are normal.
Pharmacokinetically, tirzepatide's half-life is around five days, so after your first injection it takes about four weeks of weekly doses before levels plateau in your system. That plateau (the "steady state") is when the medicine is working as consistently as it will at that dose. You can find a clear overview of how tirzepatide acts in the body on the NHS and clinical guidance we've summarised here.
Practically: your pen arrives in a plain, unbranded box via DPD, tracked to your door. It goes straight into the fridge. The KwikPen itself is pre-filled, no mixing, no measuring. Most people inject into the abdomen or thigh; the pen does the rest. If you're curious about how quickly Mounjaro begins to have an effect after that first injection, we cover the early signs in detail. Don't judge the medicine by week one.
After four weeks your prescriber typically moves you to 5 mg. This is where most people report the first unmistakeable shift: a quietening of the background noise of hunger, smaller portions feeling satisfying, less interest in snacking in the evening. These effects come from tirzepatide's dual action on GIP and GLP-1 receptors, slowing how quickly the stomach empties and signalling fullness to the brain more effectively than either pathway does alone. It is the only medicine licensed in the UK that works through both receptor types simultaneously.
Weight change during this phase tends to be modest on the scales but significant in lived experience: people eat less without fighting themselves to do it. The full Mounjaro treatment page covers the complete titration schedule and what each stage is designed to do. A useful companion read is our piece on how long it takes before the medicine fully kicks in, which goes deeper on what "working" actually means at different stages.
Side effects tend to peak around dose increases and ease off within one to two weeks. Nausea, loose stools and fatigue are the most common. Staying hydrated and eating smaller, lower-fat meals during this phase helps considerably.
This is the phase where the scales catch up with the appetite changes. Clinical trial data published in the SURMOUNT-1 trial in the New England Journal of Medicine showed average body-weight reductions of around 20–21% at the 15 mg maintenance dose over 72 weeks. Those results don't land in month one, they accumulate. At the six-month point, participants on the higher doses in SURMOUNT-1 had typically lost somewhere between 10% and 15% of starting body weight, reflecting steady progress rather than a sudden drop.
NICE, in its appraisal of tirzepatide (TA1026), notes that treatment should be reviewed if less than 5% weight loss has occurred after six months at the highest tolerated dose. That threshold is a clinical checkpoint, not a failure, it simply guides whether continuing makes sense for a given person. Prescribers at nume review this as part of every repeat consultation.
If you're thinking about the cost of reaching this stage, our Mounjaro cost page sets out what private treatment typically involves across several months, with honest context about what different price points do and don't include.
Most people reach their maintenance dose somewhere between months three and six. At that point the focus shifts from titration to consistency: weekly injections at the same dose, regular clinical reviews, and the dietary and activity habits that support the medicine's effects. Weight loss continues to accumulate at maintenance dose, just more slowly than during the titration phase.
One thing our prescribers hear regularly: people who expected dramatic early results and nearly gave up by week six, who then saw the real shift between months two and four. Our guide on how long Mounjaro takes to kick in explains why the timeline unfolds the way it does, and what to expect at each stage. Understanding that the timeline is a process, not a switch, is probably the most useful thing this page can offer. If you have specific questions about your own situation, the FAQs section covers many common concerns, and our team is reachable via the contact page seven days a week.
Mounjaro is a prescription medicine. It's not assessed or licensed for rapid or cosmetic weight loss, and results vary between individuals. A prescriber decides whether it's appropriate for you based on your full clinical picture. If you'd like to understand whether you might be eligible, you can check your eligibility through a free consultation with our clinical team.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.